RJFSA
ATOS icon

Raymond James Financial Services Advisors’s Atossa Therapeutics ATOS Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$16.4K Hold
721
– – ﹤0.01% 3407
2024
Q2 		$12.9K Hold
721
– – ﹤0.01% 3366
2024
Q1 		$19.5K Hold
721
– – ﹤0.01% 3344
2023
Q4 		$9.52K Sell
721
-81
-10% -$874 ﹤0.01% 3264
2023
Q3 		$8.86K Buy
+802
New +$11.6K ﹤0.01% 3233

Other funds holding ATOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial Services Advisors's ATOS Position: Q3 2024 in Review

Raymond James Financial Services Advisors held its Atossa Therapeutics (ATOS) position steady in Q3 2024 at 721 shares worth $16.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3407.

Raymond James Financial Services Advisors first reported a position in ATOS in Q3 2023 and has held it in 5 quarters since. The position peaked at $19.5K in Q1 2024. 86 funds tracked by Wall St. Rank hold ATOS as of Q3 2024.

  • Raymond James Financial Services Advisors held 721 shares of Atossa Therapeutics worth $16.4K as of Q3 2024.
  • Raymond James Financial Services Advisors left its Atossa Therapeutics share count unchanged in Q3 2024.
  • Atossa Therapeutics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3407 holding.
  • Raymond James Financial Services Advisors first reported a position in Atossa Therapeutics in Q3 2023 and has held it in 5 quarters since.
  • Raymond James Financial Services Advisors's Atossa Therapeutics position peaked at $19.5K in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.